Immupharma PLC Additional Listing (3736Q)

TIDMIMM

RNS Number : 3736Q

Immupharma PLC

14 October 2013

 
  FOR IMMEDIATE RELEASE     14 OCTOBER 2013

ImmuPharma plc

ADDITIONAL LISTING AND TOTAL VOTING RIGHTS

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company"), the specialist discovery and development pharmaceutical company announces that following the exercise of warrants held by the Darwin Strategic Limited ("Darwin"), application has been made to the London Stock Exchange for the admission of 750,000 new ordinary shares of 10 pence each in the Company to trading on AIM. It is expected that these new ordinary shares, which will rank pari passu with the existing ordinary shares of the Company, will be admitted to trading on 15 October 2013.

Following the allotment of the new ordinary shares, the Company's issued share capital will consist of 82,282,463 Ordinary Shares of 10p each which entitle the holder to one vote per share. Therefore, the total number of voting rights is 82,282,463.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

The warrants that Darwin exercised were issued at the same time as ImmuPharma and Darwin entered into an Equity Finance Facility ("EFF") agreement in May 2013. The EFF agreement provides ImmuPharma with a facility of up to GBP50 million which (subject to certain limited restrictions) can be drawn down at any time over the next five years. ImmuPharma is under no obligation to make a draw down and has not initiated any draw downs of this facility to date.

For further information please contact:

 
                                          + 44 (0) 20 7152 
  ImmuPharma plc                                      4080 
  Dimitri Dimitriou, Chief 
   Executive Officer 
  Dr Robert Zimmer, President 
   and Chief Scientific Officer 
  Richard Warr, Chairman 
  Tracy Weimar, Vice President, 
   Operations and Finance 
  Lisa Baderoon, Head of Investor 
   Relations                          + 44 (0) 7721 413496 
 
  Panmure, Gordon & Co., NOMAD 
   & Broker                           +44 (0) 20 7886 2500 
  Hugh Morgan, Fred Walsh, 
   Grishma Patel

This information is provided by RNS

The company news service from the London Stock Exchange

END

LISNKDDPOBDDPKD

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024